Levetiracetam Does NOT Typically Cause Absence Seizures in Adults, But Rare Paradoxical Aggravation Has Been Reported
While levetiracetam is generally considered safe and effective for treating various seizure types including generalized epilepsy, there is documented evidence that it can paradoxically aggravate absence seizures in susceptible patients, though this appears to be a rare phenomenon.
Evidence for Paradoxical Aggravation
The most direct evidence comes from a pediatric case series that identified 6 patients (2 with childhood absence epilepsy, 3 with juvenile absence epilepsy, and 1 with epilepsy with myoclonic absences) who experienced clear aggravation of absence seizures with levetiracetam 1. The aggravation showed a temporal and causal relationship with drug introduction and resolved upon dose reduction or discontinuation. While this study focused on pediatric patients, juvenile absence epilepsy extends into adulthood, making this finding relevant to adult practice.
Levetiracetam's Established Role in Epilepsy Management
Levetiracetam has become a first-line agent in modern epilepsy management. Current guidelines recommend levetiracetam as a preferred option for seizure treatment due to its efficacy and favorable tolerability profile 2. The 2024 ACEP guidelines establish levetiracetam (along with fosphenytoin and valproate) as Level A recommendations for benzodiazepine-refractory status epilepticus, with similar efficacy across all three agents 3.
Behavioral and Psychiatric Side Effects Are More Common
The FDA drug label and clinical guidelines emphasize that the primary neuropsychiatric concerns with levetiracetam are behavioral disturbances (aggression, irritability, depression, psychosis) rather than seizure aggravation 4. In adults with partial onset seizures, 13.3% experienced behavioral symptoms compared to 6.2% on placebo 4. These behavioral effects can be severe enough to require discontinuation in 1.7% of patients 4.
Clinical Approach to Suspected Levetiracetam-Induced Absence Seizures
If an adult patient develops new or worsened absence seizures after starting levetiracetam:
- Obtain EEG confirmation to document generalized 3-Hz spike-wave discharges characteristic of absence seizures, distinguishing them from complex partial seizures or behavioral side effects
- Assess temporal relationship: Did the absence seizures begin or worsen within days to weeks of levetiracetam initiation or dose increase?
- Consider alternative explanations: Tumor progression, medication non-compliance with other agents, metabolic derangements, or natural disease evolution
- Trial of dose reduction or discontinuation: If clinical suspicion is high and the patient is on other antiepileptic drugs, reduce or discontinue levetiracetam while monitoring for improvement
Important Caveats
The evidence for levetiracetam-induced absence seizures in adults is limited to case reports and extrapolation from pediatric data. The 2004 American Academy of Neurology guidelines noted insufficient evidence to recommend levetiracetam for refractory generalized tonic-clonic seizures due to small sample sizes in generalized epilepsy populations 5. However, this reflects lack of robust trial data rather than evidence of harm.
Levetiracetam remains appropriate for most adult patients with generalized epilepsy, including those with primary generalized tonic-clonic seizures 4. The risk of paradoxical aggravation appears substantially lower than the established benefits in seizure control.
When absence seizures worsen in a patient on levetiracetam, consider this rare possibility but prioritize more common explanations including disease progression, inadequate dosing of other medications, or the natural fluctuating course of epilepsy. The decision to discontinue levetiracetam should be made in consultation with neurology, weighing the strength of evidence for causation against the risks of uncontrolled seizures.